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SHORT ABSTRACT: 28 
This technique describes an efficient screening process for evaluating bacteria-specific 29 
optical imaging agents within ex vivo human lung tissue, by fibered confocal fluorescence 30 
microscopy for the rapid identification of small molecule chemical probe-candidates with 31 
translatable potential.  32 
 33 
LONG ABSTRACT: 34 
Improving the speed and accuracy of bacterial detection is important for patient 35 
stratification and to ensure the appropriate use of antimicrobials. To achieve this goal, the 36 
development of diagnostic techniques to recognize bacterial presence in real-time at the 37 
point-of-care is required. Optical imaging for direct identification of bacteria within the host 38 
is an attractive approach. Several attempts at chemical probe design and validation have 39 
been investigated, however none have yet been successfully translated into the clinic. Here 40 
we describe a method for ex vivo validation of bacteria-specific probes for identification of 41 
bacteria within the distal lung, imaged by fibered confocal fluorescence microscopy (FCFM). 42 
Our model used ex vivo human lung tissue and a clinically approved confocal laser 43 
endomicroscopy (CLE) platform to screen novel bacteria-specific imaging compounds, 44 
closely mimicking imaging conditions expected to be encountered with patients. Therefore, 45 





This technique describes a rapid screening process for evaluating bacteria-specific optical 49 
imaging agents within ex vivo human lung tissue by CLE using FCFM for the rapid 50 
identification of compounds with potential clinical utility for visualizing bacteria in the distal 51 
lung in situ.  52 
 53 
There is an urgent global requirement to ration antimicrobial prescribing in the era of rising 54 
antimicrobial resistance1. To this end, the development of diagnostic methods which act to 55 
identify bacterial infection with high specificity, sensitivity, and in real-time are highly 56 
sought2. Current techniques to confirm a diagnosis of pneumonia in critically unwell 57 
patients, such as those within intensive care units (ICUs), often rely on interpreting non-58 
specific clinical or radiological features alongside bacterial culture techniques from aspirated 59 
fluids/tissues, which can take up to 3 days to produce results. Furthermore, bacterial culture 60 
from fluid instilled into the distal lung and retrieved is prone to contamination from more 61 
proximal airways3 and is often culture negative due to concomitant antimicrobial therapy or 62 
poor sampling techniques. Additionally, molecular techniques such as polymerase chain 63 
reaction are overly sensitive when used on aspirated fluids, risking overtreatment of 64 
patients. An emerging diagnostic approach is molecular optical imaging, making in situ 65 
molecular pathology of tissues a possibility; however, the development and validation of 66 
optical imaging compounds is required. Nonetheless, direct visualization of bacteria, via 67 
activatable optical probes is potentially a very powerful method to allow the study of the 68 
presence and evolution of pneumonia in the patient, and importantly, could be used to 69 
study host-pathogen interactions in response to therapies in real-time in situ.  70 
 71 
CLE is an established investigative procedure in multiple diseases4, including within the 72 
fields of gastroenterology5, oncology6,7, and for interrogating airways and alveolar sacs8,9. It 73 
enables point-of-care structural imaging of diseased tissue using a fiber imaging bundle, 74 
which passes through the working channel of a clinical endoscope and forms direct contact 75 
with the tissue surface to be imaged by confocal microscopy. However, one limitation that 76 
remains is the need for generic contrast agents. Therefore, the use of disease specific 77 
probes, such as specific bacterial agents, could vastly expand the utility of this modality by 78 
directly visualizing bacteria at the site of suspected infection. Optical agents offer many 79 
advantages over other techniques by enabling real-time, high resolution imaging with 80 
diagnostic potential. Moreover, optical probes offer the prospect of multiplexing for 81 
interrogating multiple targets, all achieved at a relatively low cost. A number of optical 82 
agents are under development for such a purpose, however none have yet been 83 
successfully implemented within the clinic10. We have synthesized a library of small 84 
molecule chemical probes with specificity towards bacteria and developed a rapid, effective 85 
pipeline for evaluation of probe function for detecting bacterial pneumonia in situ11.  86 
 87 
To identify suitable probe candidates, the following prerequisites had to be fulfilled prior to 88 
interrogation of the probe on ex vivo human lung tissue by FCFM: i) aqueous solubility, ii) 89 
specificity and selectivity for rapidly labeling clinically relevant bacteria, iii) a high signal-to-90 
noise ratio, and iv) resistance to degradation within the lung environment. The latter was 91 
assessed by bronchoalveolar lavage fluid (BALF) from patients with acute respiratory 92 
distress syndrome (ARDS), which is a condition that is characterized by proteolytic and 93 
inflammatory environments in the lung in the ICU. Moreover, the probes had to have a 94 
 
 
suitable fluorophore for detection by a clinically approved optical CLE imaging device within 95 
human lung alveolar tissue. 96 
  97 
The pipeline to interrogate each of these prerequisites was as follows (at each stage, only 98 
probes that passed were carried forward to the next): (1) a library of probes to be 99 
investigated was synthesized; (2) each probe was added to a panel of live bacteria for 100 
confocal laser scanning microscopy (CLSM) to ensure bacterial labeling; (3) selectivity of 101 
bacterial labeling over mammalian cells in co-cultures with primary human neutrophils was 102 
established by CLSM; (4) stability and successful labeling of bacteria in the presence of the 103 
ARDS patient BALF was determined by CLSM and Matrix Assisted Laser 104 
Desorption/Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry; (5) optimal 105 
concentration of candidates was determined by CLSM, ensuring selectivity for bacteria over 106 
mammalian cells was maintained; (6) candidates were imaged by FCFM in suspension and 107 
on ex vivo human lung alveolar tissue to ensure stability and that the signal-to-noise was 108 
adequate for detection. Step 6 is described in detail within this protocol. Methodology for 109 
steps 1–5 has been previously reported11.  110 
 111 
PROTOCOL:  112 
All human lung tissue was obtained following informed consent and the study was approved 113 
by the Regional Ethics Committee. 114 
 115 
1. Preparation of Biological Samples 116 
 117 
1.1. Preparation of probes 118 
 119 
1.1.1. Make up a 1 mM stock solution of each probe (e.g., Calcein AM, UBI-3, UBI-10, etc.) 120 
in sterile dH2O, using a fine balance to weigh the freeze-dried probe compound11. Calculate 121 
the volume of dH2O to add based on the weighed mass and molecular weight of the probe. 122 
 123 
1.2. Preparation of bacterial cultures 124 
 125 
Note: For this method, Staphylococcus aureus was used as the exemplar strain. Any 126 
appropriate bacterial strain can be selected.  127 
 128 
1.2.1. Select a single colony of desired bacterial strain from a fresh Lysogeny Broth (LB) 129 
agar plate using a sterile loop. Inoculate the colony into 10 mL of LB in a 50 mL centrifuge 130 
tube by dipping the end of the loop into the culture media. Incubate at 37 °C, 250 rpm for 131 
16 h (or overnight).  132 
 133 
1.2.2. Determine the OD595 of the overnight culture by adding 100 µL of the overnight 134 
culture to 900 µL LB in a 1 mL cuvette. Measure the OD at 595 nm (using a cuvette with 1 135 
mL LB as a blank) in a spectrophotometer. Multiply the obtained OD by 10 to obtain the OD 136 
for the overnight culture.  137 
 138 
1.2.3. Subculture the overnight culture. Do this by adjusting the optical density at 595 nm 139 
(OD595) to 0.1 in 10 mL of fresh LB. Calculate the required volume of overnight culture to be 140 
 
 
added to 10 mL fresh LB to adjust the OD595 to 0.1. Incubate the culture at 37 °C, 250 rpm 141 
until the culture reaches mid-log phase (OD595 0.6–0.8), approximately 4 h.  142 
 143 
1.2.4. Measure the culture optical density (step 1.2.2) and harvest 1 x 108 colony forming 144 
units (CFU) (OD595 1 ~ 1 x 108 CFU/mL) of the bacterial culture into a 1.5 mL microtube (e.g., 145 
if the bacterial culture is OD595 0.6, collect 1.67 mL). Centrifuge the culture at 10,000 x g at 146 
room temperature for 1 min to pellet the bacteria. Wash the pellet twice in phosphate 147 
buffered saline (PBS) by resuspending (pipetting up and down carefully) the pellet in 1 mL 148 
PBS, centrifuging as above, discarding the supernatant, and repeating. Take care not to 149 
dislodge the bacterial pellet when removing the supernatant. Resuspend the final pellet in 1 150 
mL PBS. 151 
 152 
Note: Prepare as many samples as required for each labeling procedure. The protocol may 153 
be paused here for up to 1 h, followed by step 1.2.5.1, 1.2.5.2, or 1.2.5.3.  154 
 155 
1.2.5. Bacterial staining 156 
 157 
1.2.5.1. To label the bacteria with Calcein AM, add the dye to a final concentration of 158 
1 µM into the washed bacterial culture. Incubate the culture for 30 min at 37 °C with 159 
shaking at 300 rpm. Wash the counterstained bacterial suspension in PBS 3 times by 160 
centrifugation as in step 1.2.4 to remove excess dye. Resuspend in 1 mL PBS, dilute 100 µL 161 
1:1 in PBS to obtain 200 µL of OD595 0.5 Calcein AM stained bacteria. The protocol may be 162 
paused here for up to 1 h.  163 
 164 
1.2.5.2. To label the bacteria with test probes (e.g., UBI-3 or UBI-10), dilute 100 µL of 165 
the bacterial culture 1:1 in PBS to obtain OD595 0.5 in 200 µL PBS. Add either of the probes 166 
to a final concentration of 10 µM. Invert the microtube several times to ensure thorough 167 
mixing of the bacteria and the probe.  168 
 169 
Note: Imaging should be performed immediately after the addition of the probe to mimic 170 
the clinical scenario.  171 
 172 
1.2.5.3. To prepare the control unstained bacterial samples, dilute 100 µL of the 173 
culture 1:1 with PBS to obtain 200 µL of unstained OD595 0.5 sample.  174 
 175 
1.3. Preparation of ex vivo human lung tissue 176 
 177 
Note: Human lung tissue samples were obtained from patients undergoing surgical 178 
resection for lung carcinoma. All tissue used for imaging was obtained from samples of 179 
normal lung tissue away from the cancerous growth. Samples were taken fresh from the 180 
operating theatre and stored in microtubes or centrifuge tubes at -80 °C until use.  181 
 182 
1.3.1. Immediately before imaging, remove the human lung tissue sample from the freezer 183 
on dry ice. At room temperature, allow the tissue to thaw slightly; just enough to be sliced 184 




Note: The level of thawing is important; too frozen and the tissue will not slice without 187 
chipping off, too thawed and the tissue is too soft to slice. 188 
 189 
1.3.2. Using forceps, place the sliced human lung tissue into wells of a 96-well clear flat-190 
bottom tissue culture plate. Return any unused human lung tissue immediately to the 191 
storage container and place on dry ice for transport back to the -80 °C freezer.  192 
 193 
1.3.3. Add 100 µL PBS to each lung tissue sample with a pipette. Use the pipette tip to 194 
ensure all the tissue is covered in the PBS (and not stuck to the walls of the well). The tissue 195 
will swell slightly and may float. Leave the PBS on the sample for a few minutes to allow any 196 
blood to leach from the tissue into the solution. Remove as much of the PBS as possible. The 197 
tissue may block the end of the pipette tip; try to angle the plate/tip placement in order to 198 
prevent this.  199 
 200 
1.3.4. Pipette 100 µL of unstained, Calcein AM labeled, or test-probe labeled bacteria to 201 
each well containing lung tissue. Also set up controls with lung tissue and 100 µL PBS. To 202 
these control wells, probes without bacteria can be added to measure any increase in 203 
background fluorescence and/or non-specific activation of the probe by lung tissue alone. A 204 
well with lung tissue and PBS should also be included.  205 
 206 
2. Imaging with the CLE Device with FCFM 207 
 208 
2.1. Set up of CLE device 209 
 210 
Note: Prepare the CLE system 20 min before calibration to allow the laser to warm up.  211 
 212 
2.1.1. Press the on/off switch on the back of the transformer of the system and turn on the 213 
designated computer. Press the on/off button on the front of the laser scanning unit (LSU). 214 
Confirm the appearance of the green light, indicating that the unit is switched on.  215 
 216 
2.1.2. Double click on the CLE software icon. Enter the login details and wait for the LSU to 217 
initialize (10–30 s).  218 
 219 
2.1.3. For use of new FCFM imaging fibers, installation with the supplied CD is necessary. 220 
Insert the installation CD into the computer CD drive and follow the onscreen instructions. 221 
 222 
2.1.4. Clean the FCFM imaging fiber connector unit with a fiber cleaner. Rub the connector 223 
on the cleaning ribbon in a figure eight motion to remove any dust/dirt. Remove the 224 
protective yellow cap from the front of the LSU.  225 
 226 
2.1.5. Prepare the LSU hub by gently rotating the silver hub anti-clockwise until it stops. 227 
Insert the FCFM imaging fiber connector into the hub with the flat side of the connector 228 
facing upwards. Hold the fiber in place and rotate the silver hub clockwise until it clicks 229 
twice. Complete the connection by rotating the silver hub clockwise by a further 45 °.  230 
 231 
Note: If the fiber is not recognized, check that the FCFM imaging fiber has been installed and 232 




2.1.6. Follow the instructions that will pop-up for completing the FCFM imaging fiber 235 
calibration. There are 3 steps: (1) FCFM imaging fiber test (steps 2.1.7-2.1.8), (2) background 236 
acquisition (step 2.1.9), (3) fiber detection (step 2.1.10).  237 
 238 
2.1.7. Press the ‘start laser’ button on the screen. The laser will center.  239 
 240 
2.1.8. Select fresh vials (yellow: calibrate; red: clean; blue: rinse) from the calibration kit 241 
and follow the onscreen instructions: place the distal end of the FCFM imaging fiber into the 242 
yellow vial and watch for the increase in fluorescence on the monitor, then place the fiber 243 
tip into the red vial (without stirring). Wait for the fluorescence (as shown on the computer 244 
monitor) to disappear. Finally rinse the fiber tip in the blue vial.  245 
 246 
Note: If the fluorescence does not disappear, clean the FCFM imaging fiber with 8% H2O2 247 
and lens cleaning tissues and begin again. Repeat the process until satisfactory results are 248 
obtained (the image quality is clear, and no marks from dirt are apparent).  249 
 250 
2.1.9. Place the FCFM imaging fiber into the blue vial. Press ‘start laser’ followed by 251 
‘calculate’ when this becomes an option.  252 
 253 
2.1.10.  Place the FCFM imaging fiber into the yellow vial. Press ‘start laser’ followed by 254 
‘calculate’ when this becomes an option.  255 
 256 
2.1.11. During the automated calibration, clean the distal end of the FCFM imaging fiber by 257 
placing in the red vial for > 10 s, followed by the blue vial for > 4 s, as indicated by the 258 
software.  259 
 260 
2.2. Data collection with CLE 261 
 262 
2.2.1. Following setup, a window to select storage location and file prefix will open. Select 263 
the desired folder for data storage, and name the prefix accordingly.  264 
 265 
2.2.2. Place the foot pedals so that they can be easily accessed by the operator. Left pedal: 266 
laser on/off; center pedal: pause; right pedal: record/stop.  267 
 268 
Note: The laser controls can also be accessed through onscreen controls. 269 
 270 
2.2.3. Click ‘start’ onscreen or press the left foot-pedal to turn on the laser. This will start 271 
acquisition and obtain images using 100% laser power and a frame rate of 12 frames/s 272 
(default settings). 273 
 274 
Note: For other applications, these settings can be altered on screen if necessary, depending 275 
on the sample type. 276 
 277 




2.2.4.1. Insert the distal end of the FCFM imaging fiber and move the fiber slowly 280 
through the suspension to interrogate the sample.  281 
 282 
2.2.4.2. Record videos of any length (up to 10 min) by pressing the right foot pedal or 283 
selecting the onscreen record controls, as the fiber moves slowly around the sample.  284 
 285 
2.2.4.3. Clean the distal end of the FCFM imaging fiber with 8% H2O2 and lens cleaning 286 
tissues between samples. 287 
 288 
Note: Typical video lengths of 10–30s are sufficient for in vitro imaging.  289 
 290 
2.2.5. Image each of the lung tissue samples.  291 
 292 
2.2.5.1. Insert the distal end of the FCFM imaging fiber into the sample, ensuring that 293 
direct contact between the end of the fiber and the tissue is made. Gently move the end of 294 
the imaging fiber around to interrogate the sample.  295 
 296 
Note: Lifting the end of the fiber away from the tissue will remove the tissue from the focal 297 
plane; however, this may be used to image labeled bacteria that are not adhered to the 298 
tissue.  299 
 300 
2.2.5.2. Record videos of any length (up to 10 min) by pressing the right foot pedal or 301 
selecting the onscreen record controls, as the fiber moves slowly around the sample.  302 
 303 
Note: Typically, video lengths of 30s are sufficient for ex vivo imaging on tissue.  304 
 305 
2.2.5.3. Clean the distal end of the FCFM imaging fiber with lens cleaning tissues and 306 
8% H2O2 between samples. 307 
 308 
2.3. Turning off the system 309 
 310 
2.3.1. Switch the laser off by pressing the left foot pedal or by clicking the on-screen 311 
button.  312 
 313 
2.3.2. Disconnect the FCFM imaging fiber from the CLE device by turning the silver LSU hub 314 
anticlockwise until it stops. Remove the FCFM imaging fiber from the LSU hub by gently 315 
pulling the fiber connector from the LSU. 316 
 317 
2.3.3. Clean and disinfect the FCFM imaging fiber with 8% H2O2 and lens cleaning tissues. 318 
Return the protective caps to the proximal end of the FCFM imaging fiber and the front of 319 
the LSU unit. Place the fiber gently in the storage box.  320 
 321 
2.3.4. Close the data capture software and copy any saved files to an external USB device. 322 
Shut down the computer and turn off the LSU device by pressing the front panel I/O for 3 s 323 
until the green light disappears.  324 
 325 




3. Data Analysis 328 
 329 
3.1. Open the software and import the files for analysis by selecting the appropriate 330 
directory on the computer through the ‘Go to’ icon on the software dashboard. 331 
Alternatively, files can be dragged and dropped into the software dashboard.  332 
 333 
3.2. Double click on each video file to open them. The videos will automatically play with 334 
optimized color lookup table (LUT) and color table adjust. Disable the automatic intensity 335 
scaling, by clicking on the wand button above the intensity scale bar. The feature is disabled 336 
when there is no black shadowing around the button.  337 
 338 
Note: Automatic intensity scaling must be disabled to prevent continuous contrast 339 
enhancement throughout each video, making it impossible to compare and analyze videos 340 
from the same data set. 341 
 342 
3.3. Select the desired intensity scaling by moving the minimum and maximum bars to 343 
give the best contrast. Use the histogram tool when selecting the intensity scaling to ensure 344 
the broadest dynamic range is captured.  345 
 346 
Note: Ensure that the dynamic range is such that the images are not saturated (i.e. limit the 347 
white regions of the image, which indicate saturation), so that low intensity features are not 348 
missed. 349 
 350 
3.4. Once the desired scaling has been achieved, right click over the dropdown menu 351 
button listed as ‘Default (Green)’. Select the option to save the LUT. Save the LUT to a 352 
desired location. 353 
 354 
3.5. For each other video within the data set, apply the same LUT by right clicking over 355 
the ‘Default (Green)’ drop down menu and select ‘Load LUT’. Select the appropriate file to 356 
apply consistent intensity scaling to all videos within a dataset.  357 
 358 
3.6. Export processed videos by clicking on the ‘movie reel’ button. Select the desired 359 
video format, e.g. ‘for presentation purposes’, which will produce a .mpg file. Press ‘Export’ 360 
and chose file location to save the video file. Snapshots of single frames can be exported by 361 
clicking the ‘camera’ button. It is possible to save a .png, .bmp, or .jpg file. Choose the file 362 
destination and press save.  363 
 364 
Note: Videos can then be imported into any software for preparation of presentations or 365 
further quantification. Labeled bacteria are visualized as green ‘blinking’ dots in the video. 366 
The lung tissue structure will be apparent as ordered fluorescent strands, with alveolar 367 
space appearing black.  368 
 369 
REPRESENTATIVE RESULTS: 370 
In this study, we have demonstrated a method for the rapid-screening of novel bacteria-371 
specific probes in an ex vivo human alveolar lung tissue model of infection using a clinically 372 




CLE by FCFM is well suited for obtaining structural information within the distal lung, as this 375 
region (due to a high abundance of elastin and collagen) is naturally highly fluorescent when 376 
excited with a 488 nm laser8. Conversely, the alveolar space does not fluoresce, and as such 377 
enables high contrast between tissue structure and air space to be visualized (Figure 1).  378 
 379 
The addition of disease related probes or contrast agents, such as bacteria-specific probes 380 
should enable functional information about disease processes to be obtained in real-time. 381 
We have previously described the synthesis and initial in vitro screening of a library of 382 
bacteria-specific probes11; where bacterial-specificity, proteolytic stability, and retention 383 
within the bacterial membrane over time was determined. A promising bacteria-specific 384 
probe (UBI-10) was identified within the study, as well as one that showed poor retention 385 
within the bacterial cell membrane (UBI-3). These were compared to a control of 386 
commercial counterstaining (Calcein AM) that was used to labeled S. aureus. 387 
 388 
Unstained, Calcein AM, UBI-3, and UBI-10 labeled S. aureus were imaged in suspension by 389 
FCFM with 100% 488 nm laser power and a frame rate of 12 frames/s (Figure 2). Where 390 
unlabeled bacteria in PBS were imaged, no fluorescent signal was detectable. This is in 391 
contrast to when labeled bacteria were imaged. Where bacterial suspensions with UBI-3 or 392 
UBI-10 were imaged by FCFM, it was apparent that the general background fluorescence of 393 
the solution was elevated compared to PBS only controls, this is because NBD (the probe 394 
fluorophore) does emit a small amount of fluorescence signal in aqueous solution, however, 395 
bright punctate dots are clearly visible throughout the solution, without the need for a wash 396 
step. This is due to an increase in fluorescence signal emitted from NDB in a polar 397 
environment i.e., the bacterial membrane. Calcein AM is not an activatable probe, so a wash 398 
step after bacterial staining was required to remove the high fluorescent background of 399 
unbound probe in the solution. Like UBI-3 and UBI-10 labeled bacteria, bacteria labeled with 400 
Calcein AM were detected in solution by FCFM as bright green punctate dots. As the data 401 
are collected in video format, these dots appear to ‘twinkle’ as they move between cores 402 
and in-and-out of focus, a characteristic trait of imaging labeled bacteria by this method.  403 
 404 
The labeled bacteria were subsequently added to small slices of ex vivo human lung tissue 405 
and imaged again by FCFM (Figure 3). Where only PBS or unlabeled S. aureus was added to 406 
the lung tissue, only the lung tissue autofluorescent structure was detected (seen as bright 407 
green strands of collagen and elastin and dark areas of alveolar space). No punctate dots 408 
were detected for these control conditions. Similarly, only lung tissue structure (and no 409 
punctate dots) was visualized for the lung tissue condition with S. aureus plus UBI-3; 410 
indicating that this probe was not retained stably within the bacterial cell membrane i.e., it 411 
was washed out and/or is degraded in the presence of native proteolytic enzymes within 412 
the lung tissue (as previously demonstrated11).  413 
 414 
However, bright punctate dots were visible in both the Calcein AM labeled positive control 415 
S. aureus sample, and with the most promising bacteria-specific probe (UBI-10) S. aureus 416 
sample. The ‘twinkling’ dots were visible despite the strong tissue autofluorescence (Figure 417 
3). Thus, the results obtained by FCFM were in concurrence with the in vitro pre-screening 418 
of the panel of bacteria-specific probes by CLSM, and demonstrated a clinically relevant 419 




The results presented here demonstrate that the lung is an appropriate organ system for 422 
imaging by FCFM due to its distinctive autofluorescence. The bright distinctive structures 423 
allow the CLE operator to determine that they are in the alveolar space. These regions, 424 
coupled with the dark alveolar air sacs provide the perfect backdrop for imaging 425 
fluorescently labeled bacteria with high contrast. 426 
 427 
Although the detection of bacteria presented within this study is determined qualitatively 428 
by visualizing bright punctate dots, it could be possible to quantify the number of punctate 429 
dots frame by frame using a secondary software in order to further characterize probe 430 
libraries.  431 
 432 
FIGURE LEGENDS:  433 
Figure 1. Static image of human lung tissue autofluorescence. Confocal laser 434 
endomicroscopy (CLE) image of ex vivo human lung tissue using fibered confocal 435 
fluorescence microscopy (FCFM), at 488 nm excitation, 100% laser power, and 12 frames/s. 436 
Elastin and collagen are highly fluorescent (false colored green), whereas alveolar space is 437 
not, and appears as black regions. This figure has been modified from Akram et al.11 438 
 439 
Figure 2. Confocal laser endomicroscopy (CLE) image of labeled S. aureus in suspension. 440 
Fibered confocal fluorescence microscopy (FCFM) was used to image pre-labeled bacteria, 441 
at 488 nm excitation, 100% laser power, and 12 frames/s. Labeled bacteria show as highly 442 
fluorescent punctate dots (false colored green). This figure has been modified from Akram 443 
et al.11 444 
 445 
Figure 3. Confocal laser endomicroscopy (CLE) image of ex vivo human lung tissue with 446 
labeled S. aureus. Fibered confocal fluorescence microscopy (FCFM) was used to image ex 447 
vivo human lung tissue and labeled S. aureus, at 488 nm excitation, 100% laser power and 448 
12 frames/s. Labeled bacteria show as highly fluorescent punctate dots (false colored green) 449 
within the lung tissue sample when labeled with Calcein AM or UBI-10. The highest contrast 450 
is observed where bacteria are imaged within the alveolar space. This figure has been 451 
modified from Akram et al.11 452 
 453 
DISCUSSION: 454 
Lower respiratory tract infections account for the second highest burden of disease 455 
globally12,13, and a substantial rise in the number of infections attributed to antimicrobial 456 
resistant bacteria has been reported14. Pneumonia remains a common cause for 457 
hospitalization. In the ICU, the development of a pneumonia is compounded by diagnostic 458 
uncertainty and is associated with an extremely high mortality rate15. During the onset of 459 
pneumonia, bacteria proliferate within the alveolar space of the distal lung, an area that is 460 
relatively sterile, with minimal microbiota in health.  461 
 462 
This method describes relatively late stage ex vivo validation of bacteria-specific optical 463 
imaging probes11, but the design, synthesis, and probe evaluation prior to beginning this 464 




CLE is an emerging clinical technique for interrogating disease states in situ in real-time. It 467 
offers many advantages over traditional techniques for investigating suspected pulmonary 468 
pathology, which may involve a biopsy and collection of the lavage fluid. Biopsies are 469 
invasive and can cause morbidity and mortality in ventilated patients, and collected lavage 470 
fluid is often contaminated with bacteria from the upper airways. The use of CLE in the 471 
detection of pneumonia is however somewhat limited due to the poor availability of 472 
compatible imaging probes which may provide functional information of disease, despite 473 
many concerted efforts10. Combining CLE with optical agents offers the prospect of 474 
diagnosing pneumonia faster and less invasively compared to current standard practice. 475 
 476 
The critical steps to this protocol are in the sample preparation and setup of the CLE 477 
platform. Obtaining human tissue relevant to the final clinical application is also important, 478 
such as human lung tissue as demonstrated within this study. It is necessary to use human 479 
tissue because the extent of tissue autofluorescence shows large inter-species variation, and 480 
may therefore mislead the sensitivity of the bacteria-probe being imaged. Additionally, 481 
obtaining ethics for retrieval and use of human lung tissue is essential. From a technical 482 
level, correct cleaning, attachment of the imaging fiber to the imaging LSU platform, and 483 
calibration is essential for good resolution and consistent imaging, as is ensuring equivalent 484 
numbers of bacteria are added to each lung tissue sample. To further expand the utility of 485 
this method for screening panels of probes, repeating the procedure with a range of 486 
pathogens, such as those likely to be causative agents of pneumonia is necessary.  487 
 488 
The largest limitation of this technique is that the clinically approved CLE device has only 489 
one laser (488 nm). Therefore, currently, the selection of fluorophore for probe design is 490 
limited for use with this system, though clinically approved single color devices do exist with 491 
excitation wavelengths of 660 nm and near-infrared. It is highly desirable to have a second 492 
laser line implemented within the same device to enable a probe to be developed with a 493 
spectrally distinct fluorophore to improve bacteria-probe sensitivity over the level of tissue 494 
autofluorescence. Whilst dual-color CLE devices are under development, they are either not 495 
clinically approved and/or their cost is significant16.  496 
 497 
CLE in vitro using pathogenic bacteria and ex vivo human lung tissue to screen potential 498 
probes bridges the gap between conventional in vitro techniques such as flow cytometry 499 
and CLSM, and clinical utility. This step offers confidence when selecting promising 500 
compounds to carry forward to be coupled with clinical CLE imaging; and will provide 501 
indication as to whether the tested probe maintains target specificity, or demonstrates any 502 
off-target labeling, such as binding directly to tissue, or shows instability with host 503 
proteolytic enzymes. It would also be pertinent to add each of the activatable probes 504 
directly to samples of human lung tissue plus bacteria, to fully characterize the speed of 505 
probe binding and activation in real-time.  506 
 507 
We believe that our pipeline for rapidly screening novel bacteria-specific probes to assess 508 
their potential for imaging within the distal lung of patients will result in much faster 509 
translation to the clinic. This is largely because the bacteria-specific probe could be 510 
delivered locally within the lung through a catheter inserted down the working channel of a 511 
bronchoscope, meaning that microdose (< 100 µg) amounts could be delivered. Therefore, 512 
systemic delivery and biodistribution of the compound is not a concern, as is the case for 513 
 
 
many other infection targets within the body, or with nuclear imaging. Moreover, delivering 514 
the imaging probe in such a small dose reduces the risk of toxicity related complications 515 
(although toxicity screening would be required for translation). Following instillation of the 516 
probe, the catheter could then be replaced by the FCFM fiber and the same region of the 517 
lung interrogated by CLE, much the same way we have performed within this method. 518 
Imaging should be performed rapidly following installation of the probe before the probe 519 
washes away to undetectable concentrations.  520 
 521 
It is also important to note that screening of disease-identifying probes by this technique 522 
should not be limited to bacterial-imaging agents, but could also extend to the validation of 523 
probes with alternative targets, such as inflammation. This approach should also be 524 
adaptable to other disease locations within the body where imaging via FCFM is permissible.  525 
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